Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23453747 | 0.88 | AR (0.50) | ARALDH1A1HPGDNPSR1MEN1 | |
| SCHEMBL23453728 | 0.86 | MEN1 (0.57) | MEN1LMNAKMT2A | |
| SCHEMBL4229319 | 0.76 | AR (1.00) | ARNPSR1MEN1LMNAKMT2A | |
| SCHEMBL22290167 | 0.76 | NPSR1 (0.44) | ARALDH1A1HPGDSMN1; SMN2NPSR1 | |
| SCHEMBL4230856 | 0.76 | LMNA (0.62) | ARALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL6417741 | 0.75 | KDM4E (0.45) | ALDH1A1HPGDNPSR1MEN1LMNA | |
| SCHEMBL23453712 | 0.74 | PDE3B (0.54) | ARMEN1LMNAKMT2A | |
| SCHEMBL11204973 | 0.74 | KDM4C (0.49) | ARALDH1A1NPSR1LMNA | |
| SCHEMBL5568394 | 0.73 | KDM4E (0.56) | SMN1; SMN2 | |
| SCHEMBL23486367 | 0.72 | KDM4E (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171503-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | ORFAN BIOTECH SL (ES) | 2021-06-10 | — | — | US | disclosed |
| US-20140349989-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA (US) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349989-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD4, CD47 | AR 2169/4885ALDH1A1 562/4885HPGD 1312/4885 |
| US-20210171503-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | PNPO, XDH, GLS | AR 4445/4885ALDH1A1 149/4885HPGD 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.